RxDoctor Payments Data

Christopher Collins, MD

Otolaryngology · Dayton, OHNPI 1205807591

Payments from drug & device makers

$3,848in general payments, 2019–2025

Across 135 payments — averaging $28.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$1K
  • Regeneron Healthcare Solutions, Inc.$776
  • Optinose US, Inc.$554
  • Acclarent, Inc$276
  • Stryker$203
  • Intersect ENT, Inc.$201
  • plus $635 from 10 others

What the payments were for

  • Consulting fees$1003%
  • Food & beverage$3,56893%
  • Education$1805%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,848 in reported general payments places this provider in the 80th percentile of 380 otolaryngology providers in Ohio.

See all otolaryngology providers in Ohio

Medicare billing

Part B allowed, 2024
$161,743
Medicare patients
460
Services billed
2,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab18$69,193
XhanceFluticasone Propionate24$19,391
Ipratropium Bromide115$6,123
Cevimeline Hcl42$4,529
Mometasone Furoate26$1,348
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth17$1,346
CefuroximeCefuroxime Axetil21$787
Pilocarpine Hcl14$544
Omeprazole35$517
Levothyroxine Sodium29$260
Methylprednisolone31$186
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$123
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen22$107
Clindamycin Hcl13$101
Famotidine16$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$554$19,39124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 380 otolaryngology providers in Ohio.

Other otolaryngology in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →